Inversion Recovery MRI in Idiopathic Parkinson Disease Is a Very Sensitive Tool to Assess Neurodegeneration in the Substantia Nigra. Preliminary Investigation

Academic Radiology

Volumn 13, Issue 6, 2006, Pages 721-727

  Raff, Ulrich ^a   Hutchinson, Michael ^b   Rojas, Gonzalo M ^a   Huete, Isidro ^c  

^a UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Parkinson disease; segmented inversion recovery ratio imaging (SIRRIM); substantia nigra

Indexed keywords

ARTICLE; BRAIN ATROPHY; BRAIN DEGENERATION; BRAIN NERVE CELL; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DATA BASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESSENTIAL TREMOR; GRAY MATTER; HUMAN; IDIOPATHIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RATING SCALE; SUBSTANTIA NIGRA; WHITE MATTER;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; INFORMATION STORAGE AND RETRIEVAL; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PATTERN RECOGNITION, AUTOMATED; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 33646192658     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2006.01.049     Document Type: Article

References (31)

1. Parkinson J. An essay on the shaking palsy (1817), Whittingham & Rowland, London
2. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
3. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 339 (1998) 1130-1143
4. Hutchinson M., and Raff U. Parkinson's disease. a novel MRI method for determining the structural changes in the substantia nigra. J Neurol Neurosurg Psychiatr 67 (1999) 815-818
5. Hutchinson M., and Raff U. Structural changes in the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol 21 (2000) 697-701
6. Hutchinson M., Raff U., and Lebedev S. MRI correlates of pathology in parkinsonism. segmented inversion recovery ratio imaging (SIRRIM). NeuroImage 20 (2003) 1899-1902
7. Raff U., Rojas G.M., Huete I., and Hutchinson M. Computer assessment of neurodegeneration in Parkinson disease using data fusion techniques with MR images. Acad Radiol 10 (2003) 1036-1044
8. Fahn S., and Elton E.R. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D., and Goldstein M. (Eds). Recent Developments in Parkinson's Disease 2 (1987), Macmillan, London 293-304
9. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Commentary. Bethesda, Md. Clin Pharmacol Ther 69 (2001) 89-95
10. Shinotoh H., and Calne D.B. The use of PET in Parkinson's disease. Brain Cogn 28 (1995) 297-301
11. Sawle G.V., Playford E.D., Burn D.J., et al. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F18 positron emission tomography data. Arch Neurol 51 (1994) 237-243
12. Sawle G.V. The detection of preclinical Parkinson's disease. what is the role of positron emission tomography?. Mov Disord 8 (1993) 271-277
13. Hu M.T., White S.J., Herlihy A.H., Chaudhuri K.R., Hajnal J.V., and Brooks D.J. A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56 (2001) 1195-1200
14. Piccini P., and Brooks D.J. Etiology of Parkinson's disease. contributions from 18F-DOPA positron emission tomography. Adv Neurol 80 (1999) 227-231
15. Marek K., Innis R., van Dyck C., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
16. Mauricio J.C., Coelho H., Sa J., and Martins A. Importance of magnetic resonance in Parkinson disease. An analytic study of the pars compacta. Acta Med Port 3 (1990) 85-88
17. Stern M.B., Braffman B.H., Skolnick B.E., Hurtig H.I., and Grossman R.I. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 39 (1989) 1524-1526
18. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., and Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease [published erratum in Neurology 1995; 45:1420]. Neurology 45 (1995) 1138-1143
19. Antonini A., Leenders K.L., Meier D., Oertel W.H., Boesiger P., and Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 43 (1993) 697-700
20. Moriwaka F., Tashiro K., Itoh K., Hamada T., and Miyasaka K. Magnetic resonance imaging in Parkinson's disease-the evaluation of the width of the substantia pars compacta on T2 weighted images. Rinsho Shinkeigaku 32 (1992) 8-12
21. Tou J.T., and Gonzalez R.C. Pattern classification by distance functions. Pattern Recognition Principles. Edition 1981 (revived and scanned version) (1999), Addison-Wesley, Boston, MA 94-97
22. Fearnley J.M., and Lees A.J. Aging and Parkinson's disease. substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
23. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D28K immunohistochemistry. Brain 122 (1999) 1421-1436
24. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
25. Porter T., and Duff T. Compositing digital images. Comp Graphics 18 (1984) 253-259
26. Duvoisin R.C. Familial Parkinson's disease. Neurosci News 1 (1998) 43-46
27. Gasser T. Is Parkinson's disease an inherited condition?. Adv Neurol 80 (1999) 143-152
28. Koller W., Vetere-Overfield B., Gray C., et al. Environmental risk factors in Parkinson's disease. Neurology 40 (1990) 1218-1221
29. De Michele G., Filla A., Volpe G., et al. Environmental and genetic risk factors in Parkinson's disease. a case-control study in southern Italy. Mov Disord 11 (1996) 17-23
30. Hu M.T., Scherfler C., Khan N.L., et al. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. Mov Disord 20 21 (2006) 299-305
31. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508